Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123929) titled 'A clinical trial of IMP3-saRNA (YMN-136) vaccine to evaluate safety, tolerability, and preliminary antitumor activity in patients with advanced non-small cell lung cancer' on May 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Advanced non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 1
Date of First Enrollment: 2026-05-01
Target Sample Size: IMP3-saRNA (YMN-136) vaccine dose-escalation group:9;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=321449
D...